Pacira BioSciences, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Brisbane, CA
PCRX chart
What traders are saying about $PCRX
Latest postsPacira BioSciences, Inc. news
- What Pacira BioSciences Doubters Got Wrong
Simply Wall St ·
- Weekly Recap: Pending Viatris offer and Q3 revenue decline
TradingView ·
- Pacira BioSciences (PCRX) After Earnings Surprise Is The Stock Already Fully Valued
Simply Wall St ·
- Viatris (VTRS) Stock May Be Below Fair Value Despite A $1.65B Deal
Yahoo Finance ·
- Learn Why The Bull Case For Pacira BioSciences Shares Could Change Following Earnings Results
Simply Wall St ·
- Pacira BioSciences, Inc. (82P.F) Seasonal returns chart - Yahoo Finance
Yahoo Finance Singapore ·
- Viatris Inc. Q3 2026 Earnings Call Summary
app.moby.co ·
- Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX
Business Wire ·
- Pacira BioSciences 3Q 2026: Revenue $176.65M, EPS $0.7 — 10-Q Summary
TradingView ·
- Pacira BioSciences to Skip Q3 Results, Withdraw 2026 Guidance Amid Viatris Offer
TradingView ·
- Revenue falls to $177M, but profit rises at Pacira BioSciences (PCRX).
Stock Titan ·
- Does Pacira BioSciences (PCRX) Justify Its Price With Earnings?
Simply Wall St ·
Pacira BioSciences, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $726.4M | $701.0M | $675.0M | $666.8M |
| Net income | $7.0M | -$99.6M | $42.0M | $15.9M |
| Diluted EPS | $0.16 | $-2.15 | $0.89 | $0.34 |
| Total assets (year end) | $1.26B | $1.55B | $1.57B | $1.68B |
| Cash and equivalents (year end) | $158.5M | $276.8M | $153.3M | $104.1M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
- 10-Q10-Q - PCRX - 9.30.2026
- 8-K8-K
- 8-KFORM 8-K
- 10-Q10-Q - PCRX - 06.30.2026
- 8-K8-K
- 8-K8-K
- 8-K8-K
- 10-Q10-K - PCRX - 03.31.2026
- 8-K8-K
- 10-K10-K - PCRX - 12.31.2025
- 8-K8-K
- 8-K8-K
About Pacira BioSciences, Inc.
- Ticker
- PCRX (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Brisbane, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1396814
- Former names
- Pacira Pharmaceuticals, Inc., PACIRA INC, Blue Acquisition Corp
Frequently asked questions
What exchange is Pacira BioSciences, Inc. listed on?
Pacira BioSciences, Inc. trades on the Nasdaq under the ticker symbol PCRX.
What industry is Pacira BioSciences, Inc. in?
Pacira BioSciences, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Pacira BioSciences, Inc. headquartered?
Pacira BioSciences, Inc.'s business address on file with the SEC is in Brisbane, CA.
When does Pacira BioSciences, Inc.'s fiscal year end?
Pacira BioSciences, Inc.'s fiscal year ends on December 31.
How much revenue did Pacira BioSciences, Inc. report?
Pacira BioSciences, Inc. reported $726.4M in revenue for calendar year 2025, according to its SEC filings.